Sphingosine 1-phosphate receptor agonists: A patent review (2010-2012)

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 7, 2013, Pages 817-841

  Roberts, Edward ^a   Guerrero, Miguel ^a   Urbano, Mariangela ^a   Rosen, Hugh ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Autoimmune diseases; Bradycardia; Fingolimod; Lymphopenia; Relapsing remitting multiple sclerosis; Selective sphingosine 1 phosphate receptor agonists; Sphingosine 1 phosphate receptor agonists

Indexed keywords

ALDRIN; CARBOXYLIC ACID DERIVATIVE; CD4 ANTIGEN; CS 0777; FINGOLIMOD; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MORPHOLINE; PF 04629991; PHOSPHONIC ACID DERIVATIVE; PHOSPHORAMIDIC ACID DERIVATIVE; PONESIMOD; PROMETHAZINE; RECOMBINANT GAMMA INTERFERON; SIPONIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BRADYCARDIA; CROHN DISEASE; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG STRUCTURE; HEART FUNCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; LIPOPHILICITY; LUNG WEIGHT; MULTIPLE SCLEROSIS; NONHUMAN; PATENT; REVIEW;

ANIMALS; BRADYCARDIA; COGNITION DISORDERS; DRUG DESIGN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATENTS AS TOPIC; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 84879363280     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.783022     Document Type: Review

References (120)

1. Lopez Almagro R, Tarrason G, Godessart N. Protein-coupled receptors structure signaling and physiology. CUP; Cambridge: 2011
2. Blaho VA, Hla T. Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev 2011;111:6299-320
3. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010;10:489-503
4. Marsolais D, Rosen H. Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov 2009;8:297-307
5. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 2004;92:913-22 (Pubitemid 44264241)
6. Chun J, Goetzl EJ, Hla T. International union of pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 2002;54:265-9 (Pubitemid 34575716)
7. Holdsworth G, Osborne DA, Pham TCT, et al. A single amino acid determines preference between phospholipids and reveals length restriction for activation of the S1P4 receptor. BMC Biochem 2004;5:12
8. Candelore MR, Wright MJ, Tota L M, et al. Phytosphingosine 1-phosphate: a high affinity ligand for the S1P4/Edg-6 receptor. Biochem Biophys Res Commun 2002;297:600-6
9. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-60 (Pubitemid 38133663)
10. Jo E, Sanna MG, Gonzalez-Cabrera PJ, et al. S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol 2005;12:703-15 (Pubitemid 43142048)
11. Allende ML, Yamashita T, Proia RL. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 2003;102:3665-7 (Pubitemid 37409386)
12. Singleton PA, Dudek SM, Chiang ET, et al. Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. FASEB J 2005;19:1646-56 (Pubitemid 41429522)
13. Wei SH, Rosen H, Matheu MP, et al. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol 2005;6:1228-35 (Pubitemid 43045634)
14. Ozaki H, Hla T, Lee MJ. Sphingosine-1-phosphate signaling in endothelial activation. J Atheroscler Thromb 2003;10:125-31
15. LaMontagne K, Littlewood-Evans A, Schnell C, et al. Antagonism of Sphingosine-1-Phosphate Receptors by FTY720 Inhibits Angiogenesis and Tumor Vascularization. Cancer Res 2006;66:221-31 (Pubitemid 43166028)
16. Uhlig S, Gulbins E. Sphingolipids in the Lung. Am J Respir Crit Care Med 2008;178:1100-14
17. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010;9:883-97
18. FDA Drug Safety Communication: revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). Available from: http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm [Last accessed 10 December 2012]
19. Koyrakh L, Roman M I, Brinkmann V, et al. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel IKACh. Am J Transplant 2005;5:529-36 (Pubitemid 40313344)
20. Dyckman AJ. Recent advances in the discovery and development of sphingosin-1-phosphate-1 receptor agonists. Annu Rep Med Chem 2012;47:195-207
21. Gergely P, Wallstroum E, Nuesslein-Hildesheim B, et al. Phase I study with the selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans. Mult Scler 2009;15:S125
22. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med 2012;366:339-47
23. Sanna MG, Liao J, Jo E, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 2004;279:13839-48 (Pubitemid 38468916)
24. Forrest M, Sun S, Hajdu R, et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 2004;309:758-68 (Pubitemid 38542632)
25. Nofer J, van der Giet M, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004;113:569-81 (Pubitemid 38542506)
26. Takuwa N, Ohkura S, Takashima S, et al. S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. Cardiovasc Res 2010;85:484-93
27. Theilmeier G, Schmidt C, Herrmann J, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006;114:1403-9 (Pubitemid 44454560)
28. Means C K, Xiao C, Li Z, et al. Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Phys 2007;292:H2944-51 (Pubitemid 47084545)
29. Fischer I, Alliod C, Martinier N, et al. Sphingosine kinase 1 and sphingosine 1-phosphate receptor 3 are functionally upregulated on astrocytes under pro-inflammatory conditions. PLoS One 2011;6:e23905
30. Hsu A, Zhang W, Lee J, et al. Sphingosine-1-phosphate receptor-3 signaling up-regulates epidermal growth factor receptor and enhances epidermal growth factor receptor-mediated carcinogenic activities in cultured lung adenocarcinoma cells. Int J Oncol 2012;40:1619-26
31. Marsolais D, Hahm B, Edelmann KH, et al. Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza. Mol Pharmacol 2008;74:896-903
32. Golfier S, Kondo S, Schulze T, et al. Shaping of terminal megakaryocyte differentiation and proplatelet development by sphingosine-1-phosphate receptor S1P4. FASEB J 2010;24:4701-10
33. Ley S, Weigert A, Weichand B, et al. The role of TRKA signaling in IL-10 production by apoptotic tumor cell-activated macrophages. Oncogene 2012;1-10
34. Sekar D, Hahn C, Brune B, et al. Apoptotic tumor cells induce IL-27 release from human DCs to activate Treg cells that express CD69 and attenuate cytotoxicity. Eur J Immunol 2012;42:1585-98
35. Ohotski J, Long JS, Orange C, et al. Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. Br J cancer 2012;106:1453-9
36. Malek RL, Toman RE, Edsall LC, et al. Nrg-1 belongs to the endothelial differentiation gene family of G protein-coupled sphingosine-1-phosphate receptors. J Biol Chem 2001;276:5692-9
37. Jung CG, Kim HJ, Miron VE, et al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 2007;55:1656-67 (Pubitemid 47612852)
38. Walzer T, Chiossone L, Chaix J, et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol 2007;8:1337-44 (Pubitemid 350131171)
39. van Doorn R, Pinheiro MA, Kooij G, et al. Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier. J Neuroinflam 2012;9:133
40. Allergan, Inc. Coumarin compounds as receptor modulators with therapeutic utility. WO011050054; 2011
41. Allergan, Inc. Biphenyl oxadiazole derivatives as sphingosine-1-phosphate (S1P) receptor modulators. US0110257232; 2011
42. Allergan, Inc. 3-(4-((1H-imidazol-1-yl) methyl)phenyl)-5-aryl-1,2,4- oxadiazole derivatives as sphingosine-1-phosphate (S1P) receptor modulators. WO011136927; 2011
43. Allergan, Inc. Novel phosphonic acids as S1P receptor Modulators. WO012071212; 2012
44. Allergan, Inc. Novel azetidine derivatives as sphingosine-1-phosphate (S1P) receptor modulators. WO012074703; 2012
45. Allergan, Inc. Novel phenyl oxadiazole derivatives as sphingosine-1-phosphate (S1P) receptor modulators. WO012074732; 2012
46. Allergan, Inc. Indole derivatives as modulators of S1P receptors. WO012071184; 2012
47. Allergan, Inc. Novel oxadiazole derivatives as sphingosine-1-phosphate (S1P) receptor modulators. WO012074718; 2012
48. Allergan, Inc. Novel pyridine derivatives as sphingosine-1-phosphate (S1P) receptor modulators. WO012074719; 2012
49. Allergan, Inc. Novel benzyl azetidine derivatives as sphingosine-1- phosphate (S1P) receptor modulators. WO012074722; 2012
50. Allergan, Inc. Oxadiazole derivatives as sphingosine-1-phosphate (S1P) receptor modulators. WO012074730; 2012
51. Allergan, Inc. Modulators of S1P receptos. WO012071186; 2012
52. Allergan, Inc. Alkyne and alkene derivatives as sphingosine-1-phosphate (S1P) receptor modulators. WO012074921; 2012
53. Allergan, Inc. Novel azetidine derivatives as sphingosine-1-phosphate (S1P) receptor modulators. WO012074926; 2012
54. Allergan, Inc. Novel oxime azetidine derivatives as sphingosine-1- phosphate (S1P) receptor modulators. WO012074780; 2012
55. Allergan, Inc. Novel oxime derivatives as sphingosine-1-phosphate (S1P) receptor modulators. WO012074782; 2012
56. Allergan, Inc. Novel compounds as receptor modulators with therapeutic utility. WO011066179; 2011
57. Allergan, Inc. Novel compounds as receptor modulators with therapeutic utility. WO012071278; 2012
58. Allergan, Inc. Substituted bicyclic methyl amine derivatives as sphingosine-1-phosphate (S1P) receptor modulators. WO012145236; 2012
59. Allergan, Inc. Substituted bicyclic methyl azetidines as sphingosine-1-phosphate (S1P) receptor modulators. WO012142255; 2012
60. Allergan, Inc. Novel compounds as receptor modulators with therapeutic utility. WO011066184; 2011
61. Allergan, Inc. Aromatic compounds having sphingosine-1-phosphate (S1P) receptor activity. WO011143332; 2011
62. Allergan, Inc. Bicyclic methyl amine derivatives as sphingosine-1- phosphate (S1P) receptor modulators. WO012142377; 2012
63. Allergan, Inc. Phenyl bicyclic methyl amine derivatives as sphingosine-1-phosphate (S1P) receptor modulators. WO012142288; 2012
64. Allergan, Inc. Phenyl bicyclic methyl azetidine derivatives as sphingosine-1-phosphate (S1P) receptor modulators. WO012142268; 2012
65. Allergan, Inc. Novel alkene derivatives as sphingosine-1-phosphate (S1P) receptor modulators. WO012074898; 2012
66. Glaxo Group Ltd. 1,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists. WO010145203; 2010
67. Glaxo Group Ltd. Thiazole or thiadizaloe derivatives for use as sphingosine 1-phosphate 1 (S1P1) receptor agonists. WO010145202; 2010
68. Glaxo Group Ltd. Thiadiazole derivatives and their use for the treatment of disorders mediated by SlPl receptors. WO010146104; 2010
69. Glaxo Group Ltd. S1P1 agonists comprising a bicyclic N-containing ring. WO010146105; 2010
70. Glaxo Group Ltd. 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists. WO010148650; 2010
71. Glaxo Group Ltd. 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists. WO010148649; 2010
72. Glaxo Group Ltd. Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists. WO011072488; 2011
73. Glaxo Group Ltd. Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (S1P1) receptor agonists. WO011113309; 2011
74. Glaxo Group Ltd. Compounds as agonists of S1P1 receptors. WO011134280; 2011
75. Almirall SA. New 2-amidothiadiazole derivatives. WO010043377; 2010
76. Almirall SA. New thiadiazole derivatives. WO011035900; 2011
77. Almirall SA. New 2-aminothiadiazole derivatives. WO011069647; 2011
78. Almirall SA. 1,2,4-oxadiazole derivatives and their therapeutic use. WO010072352; 2010
79. Almirall SA. New oxadiazole derivatives. WO011113578; 2011
80. Almirall SA. S1P1 receptor agonists for use in the treatment of multiple sclerosis. EP2455080; 2012
81. Almirall SA. S1P1 receptor agonists for use in the treatment of Crohn's disease. EP2455081; 2012
82. Almirall SA. Pyrazole derivatives as S1P1 agonists. WO011144338; 2011
83. Almirall SA. Oxadiazole derivatives as slpl receptor agonists. WO010081692; 2010
84. Sanofi-Aventis. Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring. WO011086080; 2011
85. Sanofi-Aventis. Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring. WO011086079; 2011
86. Sanofi-Aventis. Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring. WO011086078; 2011
87. Sanofi-Aventis. Carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring. WO011086077; 2011
88. Sanofi-Aventis. 2,5-substituted oxazolopyrimidine derivatives. WO011086081; 2011
89. Sanofi-Aventis. 2,5,7-substituted oxazolopyrimidine derivatives. WO011086075; 2011
90. Sanofi-Aventis. Oxazolopyrimidines as EDG-1 receptor agonists. WO010006704; 2010
91. Merck Serono SA. Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis. WO010069949; 2010
92. Merck Serono SA. Oxazole pyridine derivatives useful as S1P1 receptor agonists. WO010100142; 2010
93. Merck Serono SA. Oxadiazole derivatives. WO010112461; 2010
94. Merck Serono SA. Oxadiazole derivatives. WO010115751; 2010
95. Merck Serono SA. Pyrazole oxadiazole derivatives as S1P1 agonists. WO010142628; 2010
96. Merck Serono SA. 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (S1P) receptors. WO012004287; 2012
97. Abbott Laboratories. Novel oxadiazole compounds. WO011071570; 2011
98. Abbott Laboratories. Agonists and antagonists of the S1P5 receptor, and methods of uses thereof. WO010093704; 2010
99. Abbott Laboratories. (Thio)morpholine derivatives as S1P modulators. WO011023795; 2011
100. Abbott Laboratories. Bisaryl(thio) morpholine derivatives as S1P modulators. WO012004375; 2012
101. Abbott Laboratories. Fused heterocyclic derivatives as S1P modulators. WO012004373; 2012
102. Abbott Laboratories. Spiro-cyclic amine derivatives as S1P modulators. WO012004378; 2012
103. Biogen Indec Ma, Inc. Bicyclic aryl sphingosine 1-phosphate analogs. WO010051030; 2010
104. Biogen Indec Ma, Inc. Heterobicyclic sphingosine 1-phosphate analogs. WO010051031; 2010
105. Biogen Indec Ma, Inc. Bicyclic aryl sphingosine 1-phosphate analogs. WO011017561; 2011
106. Biogen Indec Ma, Inc. S1P modulating agents. WO012109108; 2012
107. Receptos, Inc. Selective heterocyclic Sphingosine 1 phosphate receptor modulators. WO011060391; 2011
108. Receptos, Inc. Selective heterocyclic Sphingosine 1 phosphate receptor modulators. WO012158550; 2012
109. Receptos, Inc. Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis. WO011060389; 2011
110. Receptos, Inc. Selective Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis. WO011060392; 2011
111. Novartis AG. Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation. WO010010127; 2010
112. Novartis AG. Immunosuppressant compounds and compositions. WO004103306; 2004
113. Novartis AG. Immunosuppressant compounds and compositions. WO005000833; 2005
114. Novartis AG. FTY720 halogenated derivatives. WO011070066; 2011
115. Akaal Pharma PTY Ltd. S1P receptors modulators. WO010042998; 2010
116. Akaal Pharma PTY Ltd. S1P receptors modulators and their use thereof. WO010043000; 2010
117. Actelion Pharmaceuticals Ltd. 2-methoxy-pyridin-4-yl derivatives. WO012098505; 2012
118. Actelion Pharmaceuticals Ltd. Pyridin-4-yl derivatives as immunomodulating agents. WO008029371; 2008
119. Astellas Pharma, Inc. 2H-chromene compound and derivative thereof. US0120178735; 2012
120. Bioprojet. Sun Pharma Advance Research Co. Ltd. Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists. WO012140020; 2012